Anastasia (Stacy) Henry is a Senior Director and Staff Scientist at Denali Therapeutics, where she leads a team within the Pathway Biology group. Stacy has served as the project leader for Denali’s DNL310 program, a blood-brain-barrier-penetrant enzyme replacement therapy for MPS II disease, and leads the biology efforts supporting the LRRK2 kinase inhibitor program, both of which are now in late-stage clinical studies. She earned her Ph.D. from the University of California, San Francisco, under the mentorship of Mark von Zastrow, and completed her postdoctoral training in the Neuroscience Department at Pfizer in Warren Hirst’s lab.
Co-PI (Core Leadership)
Anastasia Henry, PhD
Denali Therapeutics
Anastasia (Stacy) Henry is a Senior Director and Staff Scientist at Denali Therapeutics, where she leads a team within the Pathway Biology group. Stacy has served as the project leader for Denali’s DNL310 program, a blood-brain-barrier-penetrant enzyme replacement therapy for MPS II disease, and leads the biology efforts supporting the LRRK2 kinase inhibitor program, both of which are now in late-stage clinical studies. She earned her Ph.D. from the University of California, San Francisco, under the mentorship of Mark von Zastrow, and completed her postdoctoral training in the Neuroscience Department at Pfizer in Warren Hirst’s lab.
